Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
(HealthDay News) — Patients with nonerosive gastroesophageal reflux disease (GERD) do not have an increased risk for esophageal adenocarcinoma compared with the general population, according to a study published online Sept. 13 in The BMJ.
Dag Holmberg, M.D., Ph.D., from Karolinska Institutet in Stockholm, and colleagues conducted a population-based cohort study to examine the incidence rate of esophageal adenocarcinoma among patients with nonerosive GERD versus the general population. A total of 486,556 adults who underwent endoscopy were included: 285,811 were included in the nonerosive GERD cohort and 200,745 were in the validation cohort with erosive GERD.
The researchers found that during 2,081,051 person-years of follow-up, 228 of the patients with nonerosive GERD developed esophageal adenocarcinomas (incidence rate, 11.0/100,000 person-years). The incidence was comparable to that in the general population, and no increase was seen in incidence with longer follow-up. Among those with erosive esophagitis at endoscopy, there were 542 esophageal adenocarcinomas during 1,750,249 person-years (incidence rate, 31.0/100,000 person-years), with an increased overall standardized incidence ratio of 2.36, which became more pronounced with longer follow-up.
“Our study suggests that these repeated gastroscopies are probably unnecessary for people with reflux disease who have a normal esophageal mucosa,” Holmberg said in a statement. “These findings should be reassuring for this large patient group and can guide general practitioners who often treat them.”
